Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for CytomX Therapeutics (CTMX) over the last 9 years, with Q3 2025 value amounting to $4.3 million.

  • CytomX Therapeutics' Other Non-Current Liabilities rose 606.96% to $4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 606.96%. This contributed to the annual value of $4.1 million for FY2024, which is 570.25% up from last year.
  • Latest data reveals that CytomX Therapeutics reported Other Non-Current Liabilities of $4.3 million as of Q3 2025, which was up 606.96% from $4.2 million recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' Other Non-Current Liabilities peaked at $4.3 million during Q3 2025, and registered a low of $216000.0 during Q2 2023.
  • Over the past 3 years, CytomX Therapeutics' median Other Non-Current Liabilities value was $4.0 million (recorded in 2024), while the average stood at $3.6 million.
  • Over the last 5 years, CytomX Therapeutics' Other Non-Current Liabilities had its largest YoY gain of 174861.11% in 2024, and its largest YoY loss of 570.25% in 2024.
  • Over the past 3 years, CytomX Therapeutics' Other Non-Current Liabilities (Quarter) stood at $3.9 million in 2023, then rose by 5.7% to $4.1 million in 2024, then grew by 4.47% to $4.3 million in 2025.
  • Its Other Non-Current Liabilities was $4.3 million in Q3 2025, compared to $4.2 million in Q2 2025 and $4.2 million in Q1 2025.